Antibodies in Clinic / Clinical Trials

Antibody engineering has revolutionized the development of therapeutic antibodies by introducing mutations that modulate various aspects of antibody function. This overview provides a concise summary of key mutation strategies in antibody engineering, including their benefits and challenges.

 ...

Antibody-dependent cell-mediated cytotoxicity (ADCC) is a crucial mechanism in the immune response and a primary mode of action for many therapeutic antibodies. Enhancing ADCC through strategic mutations in the antibody structure has become a focal point in antibody engineering...

The neonatal Fc receptor (FcRn) has long been recognized for its role in regulating the half-life of IgG and albumin. However, recent research has uncovered its potential as a versatile drug delivery system. This blog post will explore the multifaceted roles of FcRn and its emerging applications in drug...

The field of cancer immunotherapy has witnessed remarkable advancements in recent years, with immune checkpoint inhibitors (ICIs) at the forefront of this revolution. However, as the limitations of ICIs become...

Antibody therapeutics have made significant strides in recent years, with several successful treatments already in the market. However, the future of this field lies in the promising candidates currently in Phase I-II clinical trials. These antibodies, targeting a wide range of diseases, have the potential to become important treatments in the coming years.

One such antibody is DSP-0038, a humanized monoclonal antibody targeting the TROP2...

Introduction

Tabalumab...

1. Background study

In both relapsed and refractory categories, patients with multiple myeloma (MM), a blood malignancy, do not show any improvement or at least a minor response after sixty days of starting treatment [1]. With an occurrence of 4.5 to 6 per 100,000 yearly, MM accounts for 1.8% of all new cancer cases and 2.1% of all cancer-related deaths in the United States each year [2]. MM presently has 160,000...

Introduction

Aducanumab...

1.  Background study

Solid tumors are abnormal cell division without any cysts or liquid, such as sarcomas and carcinomas [1]. According to the American Cancer Society (ACS), around 90% of adult and 40 % of children cancers are associated with solid tumors [2]. Several effective medications exist, including antibody therapies in solid tumors [3]. However, Alsevalimab as a glycoengineered antibody makes a significant...

Bispecific antibodies have emerged as a promising class of therapeutic agents in the field of cancer immunotherapy. As of August 2023, several bispecific antibodies were in various stages of development and clinical trials, showing great potential for improving cancer treatment outcomes.

One of the most notable bispecifics is blinatumomab (Blincyto), a CD19/CD3 bispecific approved for treating acute lymphoblastic leukemia (ALL) that has demonstrated...